Pro investors have been piling into these five stocks in the third quarter. Here's everything you need to know.
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
With a pair of Phase III trials coming up for its dermatological drug, Novan CEO Nate Stasko says the company is merely piercing the skin of its long-term potential.
Health care stocks in general are under pressure until after the U.S. presidential election, Cramer says.
DuPont expects earnings to jump 30% in the full year.
These four stocks have soared in 2016. Here are the reasons and a look at whether there is still time to jump aboard.
Third time was the charm for Alkermes' experimental antidepressant ALKS 5461.